BioCentury | Nov 14, 2020
Politics, Policy & Law

U.K.’s opportunity as changes come to MHRA, NICE

On the cusp of a new era outside of Europe, the U.K. has an opportunity to create an innovative and interconnected regulatory and reimbursement system that can attract biopharma by accelerating patient...
BioCentury | Aug 11, 2020
Finance

AI play Atomwise to build internal pipeline with $123M series B

After building and validating its AI-driven small molecule discovery platform through partnerships, Atomwise has raised a $123 million series B round that will enable the company to begin building its own pipeline.  Since its 2012...
BioCentury | May 4, 2020
Deals

Stemline takeout gives Menarini U.S. oncology beachhead

Although Menarini will gain a modest-selling drug by acquiring Stemline for up to $677 million, the Italian biopharma will also establish a U.S. oncology presence as its cancer pipeline matures. The deal gives Menarini Group...
BioCentury | Jan 28, 2020
Company News

Jan. 27 Company Quick Takes: Enhertu meets in pivotal gastric cancer study; plus Biocon-Mylan, CMS, Lilly-Boehringer, Ningbo-Genentech

Japan submission on horizon for AZ, Daiichi’s ADC Daiichi Sankyo Co. Ltd. (Tokyo:4568) plans to seek approval of Enhertu for gastric cancer starting in Japan after the anti-HER2 antibody-drug conjugate met the primary and a...
BioCentury | Nov 15, 2019
Financial News

Atomwise JV raises $14.5M series A to advance AI-discovered candidates

X-37 raised a $14.5 million series A to move forward AI platform-generated programs from Atomwise, which launched the JV last year with Velocity Pharmaceutical Development. DCVC Bio led Thursday’s round, with participation from Alpha Intelligence...
BioCentury | Oct 17, 2019
Financial News

Oct. 16 Financial Quick Takes: Hong Kong IPO could value Ascentage at $876M; plus Principia, Rhythm, ProQR, dMed, Ionova and Amarna

Ascentage sets Hong Kong IPO terms Ascentage Pharma Group International would raise HK$404.4 million ($51.6 million) and be valued at HK$6.9 billion ($876.4 million) if it prices its Hong Kong IPO at the mid-point of...
BioCentury | Jul 19, 2019
Company News

July 18 Company Quick Takes: Mallinckrodt, Silence in RNAi deal; plus Pear, Blueprint and more

Mallinckrodt licenses RNAi candidate from Silence Mallinckrodt plc (NYSE:MNK) obtained an exclusive, worldwide license to C3-targeted RNAi therapy SLN500 from Silence Therapeutics plc (LSE:SLN), plus options to license up to two additional complement-targeted preclinical candidates....
BioCentury | May 15, 2019
Distillery Therapeutics

Inhibiting PIM2 sensitizes CML to Gleevec

...Cancer INDICATION: Chronic myelogenous leukemia (CML) Patient sample, cell culture and mouse studies suggest inhibiting PIM2...
...Pharmaceuticals LLC has the oral PIM2 inhibitor JP-11646 in preclinical testing for MM. TARGET/MARKER/PATHWAY: Pim-2 (PIM2...
...imatinib mesylate (QTI571, CGP 57148B, Ruvise, STI-571) PIM447, lgh447 University of Massachusetts Medical School BCR-ABL tyrosine kinase (BCR-ABL) Pim-2 (PIM2) Stem...
BioCentury | Nov 9, 2018
Clinical News

Mallinckrodt Niemann-Pick disease therapy fails pivotal trial

Mallinckrodt plc (NYSE:MNK) said VTS-270 showed no significant separation from placebo in a Phase IIb/III trial to treat Niemann-Pick disease type C1 (NPC1). Mallinckrodt CSO and EVP Steven Romano disclosed the result on a conference...
BioCentury | Nov 6, 2018
Clinical News

Mallinckrodt Niemann-Pick disease therapy fails pivotal trial

Mallinckrodt plc (NYSE:MNK) said VTS-270 showed no significant separation from placebo in a Phase IIb/III trial to treat Niemann-Pick disease type C1 (NPC1). Mallinckrodt CSO and EVP Steven Romano disclosed the result on a conference...
Items per page:
1 - 10 of 91